Skip to content

Clinical trials

Idiopathic Pulmonary Fibrosis trials in the United States

Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.

Filters: Condition: Idiopathic Pulmonary Fibrosis Country / region: United States Clear all

235 trials match Source: ClinicalTrials.gov registrations

Trials started per year

By phase, 2000 to 2026.

Trials started per year
CategoryTrials
20002
20012
20021
20037
20042
20056
20063
20076
20088
20098
20106
20117
20128
201312
20143
201511
201611
201711
201815
201911
202014
20219
202217
202314
202412
202511
202615

Status

Trials by registry status. Select a bar to filter.

Trials by status
CategoryTrials
Completed132
Terminated37
Recruiting29
Active, not recruiting15
Unknown status7
Withdrawn7
Not yet recruiting4
Enrolling by invitation2
Suspended1
Approved for marketing1

Top lead sponsors

A sponsor with a page on Pharma Observatory links to it.

Top lead sponsors
CategoryTrials
Boehringer Ingelheim18
Bristol-Myers Squibb7
Duke University7
Hoffmann-La Roche7
Genentech, Inc.6
National Jewish Health6
University of Alabama at Birmingham6
Gilead Sciences5
InterMune5
Kyntra Bio5

Top conditions

MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.

Top conditions
CategoryTrials
Idiopathic Pulmonary Fibrosis235
Pulmonary Fibrosis54
Lung Diseases, Interstitial45
Fibrosis19
Lung Diseases16
Idiopathic Interstitial Pneumonias11
Hypertension, Pulmonary9
Pulmonary Arterial Hypertension7
Sarcoidosis7
Pulmonary Disease, Chronic Obstructive6

Trials

Showing 1 to 25 of 235. Each trial links to its page on Pharma Observatory.

135 more trials match. See them on Pharma Observatory

Recently changed trials

Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.

Go deeper on Pharma Observatory

Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.